Skip to Content
Merck

Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype.

Cancer cell (2016-04-07)
Timothy N Phoenix, Deanna M Patmore, Scott Boop, Nidal Boulos, Megan O Jacus, Yogesh T Patel, Martine F Roussel, David Finkelstein, Liliana Goumnerova, Sebastien Perreault, Elizabeth Wadhwa, Yoon-Jae Cho, Clinton F Stewart, Richard J Gilbertson
ABSTRACT

The childhood brain tumor, medulloblastoma, includes four subtypes with very different prognoses. Here, we show that paracrine signals driven by mutant β-catenin in WNT-medulloblastoma, an essentially curable form of the disease, induce an aberrant fenestrated vasculature that permits the accumulation of high levels of intra-tumoral chemotherapy and a robust therapeutic response. In contrast, SHH-medulloblastoma, a less curable disease subtype, contains an intact blood brain barrier, rendering this tumor impermeable and resistant to chemotherapy. The medulloblastoma-endothelial cell paracrine axis can be manipulated in vivo, altering chemotherapy permeability and clinical response. Thus, medulloblastoma genotype dictates tumor vessel phenotype, explaining in part the disparate prognoses among medulloblastoma subtypes and suggesting an approach to enhance the chemoresponsiveness of other brain tumors.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Caspase 3 Antibody, active (cleaved) form, Chemicon®, from rabbit
Sigma-Aldrich
Anti-Active-β-Catenin (Anti-ABC) Antibody, clone 8E7, clone 8E7, Upstate®, from mouse
Sigma-Aldrich
Anti-GLUT-1 Antibody, CT, from rabbit, purified by affinity chromatography
Sigma-Aldrich
Anti-PLVAP antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution